Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Brazilian Journal of Medical and Biological Research April 1, 2006 Antônio Waldo Zuardi, J.a.s. Crippa, Jaime E. C. Hallak et al. 411 citations
A high dose of delta9-tetrahydrocannabinol, the main psychoactive component of cannabis, induces anxiety and psychotic-like symptoms in healthy volunteers, and these effects are significantly reduced by cannabidiol (CBD), a cannabis constituent without typical cannabis effects. Studies in animal models and healthy volunteers suggest an anxiolytic-like effect of CBD. Its antipsychotic-like properties have been investigated in animal models and supported by studies on healthy volunteers using binocular depth inversion and ketamine-induced psychotic symptoms. Open case reports and a preliminary controlled clinical trial indicate that CBD may be a safe, well-tolerated alternative treatment for schizophrenia. Future studies in other psychotic conditions are indicated.